Optimi Health (OPTH) FDA Approvals

$1.99 -0.11 (-5.24%)
As of 12:05 PM Eastern

Upcoming FDA Events for Optimi Health

Optimi Health (OPTH) has upcoming FDA regulatory milestones for psilocybin-assisted therapy. The table below outlines estimated target dates and event types for these pending regulatory actions.

DrugTarget DateAnnouncement
psilocybin-assisted therapyH1 2027Trial Initiation
Optimi Health Corp announced that the trial is planned to be initiated in the first half of 2027 (September 10, 2026)
psilocybin-assisted therapyLATE 2027Dose Update
Optimi Health Corp. announced that the dosing expected to be complete by the end of 2027. (September 10, 2026)

Optimi Health's Drugs in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by Optimi Health (OPTH). Over the past two years, Optimi Health has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as OPTI-201 and psilocybin-assisted. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Select a button below to view the list of FDA events for that drug.

OPTI-201 FDA Regulatory Events

OPTI-201 is a drug developed by Optimi Health for the following indication: in Major Depressive Disorder. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Psilocybin-assisted therapy FDA Regulatory Timeline and Events

Psilocybin-assisted therapy is a drug developed by Optimi Health for the following indication: for Major Depressive Disorder. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Optimi Health FDA Events - Frequently Asked Questions

In the past two years, Optimi Health (OPTH) has not received FDA approval for any therapies. However, the company does have drugs under review or in active clinical development.

In the past two years, Optimi Health (OPTH) has reported FDA regulatory activity for the following drugs: psilocybin-assisted therapy and OPTI-201.

The most recent FDA-related event for Optimi Health occurred on November 18, 2026, involving OPTI-201. The update was categorized as "Provided Update," with the company reporting: "Optimi Health Corp provides an update on its clinical programs, commercial supply, Ibogaine Initiative and a shares-for-debt settlement."

Current therapies from Optimi Health in review with the FDA target conditions such as:

  • for Major Depressive Disorder - psilocybin-assisted therapy
  • in Major Depressive Disorder - OPTI-201
  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

FDA progress for NASDAQ:OPTH last updated on 11/18/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
From Our Partners